首页> 外国专利> DERIVATIVES OF AZAINDOL WITH A COMBINATION OF PARTIAL AGONISM OF THE NICOTINE RECEIVER OF ACETILCOLINE AND INHIBITION OF DOPAMINE REABSORTION.

DERIVATIVES OF AZAINDOL WITH A COMBINATION OF PARTIAL AGONISM OF THE NICOTINE RECEIVER OF ACETILCOLINE AND INHIBITION OF DOPAMINE REABSORTION.

机译:氮杂吲哚衍生物与乙酰胆碱的尼古丁受体的部分失神症和多巴胺的再吸收抑制相结合。

摘要

Compounds derived from azaindole, characterized by the general formula (I): or a tautomer, stereoisomer, N-oxide, or a pharmacologically acceptable salt, hydrate or solvate, of any of the foregoing, wherein - X, Y and Z independently represent N or C, with the proviso that the ring contains at least one atom of N, and not more than 2, - m and n are independently or 0 (zero) or 1, with the proviso that when Y and Z represent carbon and X represents nitrogen, m is 0 (zero), - R2 and R3 independently represent hydrogen, halogen, (C1-3) alkyl, alkynyl (C1-3), NH-alkyl (C1-3), CF3, hydroxyl, alkyl (C1 -3) oxy or a piperidinyl, pyrrolidinyl, tetrahydropyridinyl, morpholinyl, azepanyl, 1-azabicyclo [2.2.2] octanyl or 1-aza-bicyclo [2.2.2] oct-2-enyl group, group that is unsubstituted or substituted with one or more substituents selected from halogen, (C1-3) alkyl, phenyl or benzyl, - R4, R5 and R6 independently represent hydrogen, halogen or, (C1-3) alkyl, (C2-3) alkynyl, CF3, NH (C1-3) alkyl, hydroxyl or (C1-3) alkyl oxy, with the proviso that R4 exists only when Y = C, and R5 only when Z = C, with the proviso that when X and Z are N, Y is C, R4 is Cl, R5 and R6 are H, myn are zero (0), and R2 is H, R3 is not iodine or 1 , 2,3,6-tetrahydropyridin-4-yl; with the proviso that when X is N, Y and Z are C, R4 is Cl, R5 is Br, R6 is H, m and n are zero (0), and R3 is H, R2 is not iodine or H; with the proviso that when X and Z are C, Y is N, R5 is hydroxy, R2, R4 and R6 are H, m and n are zero (0), R3 is not 1,2,3,6-tetrahydropyridin-4- With the condition that when X is N, Y and Z are C, myn are zero (0), R2, R3, R4 and R5 are H, R6 is not chlorine or fluorine, with the proviso that when X is N , Y and Z are C, myn are zero (0), R2, R3, R4 and R6 are H, R5 is not bromine, chlorine or fluorine, with the proviso that when X is N, Y and Z are C, m is 1, n is zero (0), R2, R4, R5 and R6 are H, R3 is not ethyl or morpholin-4-yl, with the proviso that when X is N, Y and Z are C, m and n are zero (0), R2, R4, R5 and R6 are H, R3 is not bromine, with the proviso that when X is N, Y and Z are C, m and n are zero (0), R2, R3, R5 and R6 are H, R4 is not chlorine, with the proviso that when X is N, Y and Z are C, m is zero (0), n is 1, R3, R4, R5 and R6 are H, R2 is not hydrogen or pyridine -4-yl, with the proviso that when X is N, Y and Z are C, m is zero (0), n is 1, R4, R5 and R6 are H, R3 is bromine, R2 it is not pyridin-4-yl, 2-methylpyridinyl-4-yl, -ethyl-pyridinyl-4-yl or morpholin-4-yl.
机译:衍生自氮杂吲哚的化合物,其特征在于通式(I):或上述任一项的互变异构体,立体异构体,N-氧化物或药学上可接受的盐,水合物或溶剂化物,其中-X,Y和Z独立地表示N或C,条件是该环包含至少一个N原子且不超过2个原子,-m和n独立地为0(零)或1,条件是当Y和Z表示碳,X表示氮,m为0(零),-R2和R3分别代表氢,卤素,(C1-3)烷基,炔基(C1-3),NH-烷基(C1-3),CF3,羟基,烷基(C1- 3)未被取代或被一个取代的氧基或哌啶基,吡咯烷基,四氢吡啶基,吗啉基,氮杂基,1-氮杂双环[2.2.2]辛基或1-氮杂双环[2.2.2]辛-2-烯基选自卤素,(C1-3)烷基,苯基或苄基的一个或多个取代基,-R4,R5和R6独立地表示氢,卤素或(C1-3)烷基,(C2-3)炔基,CF3,NH(C1 -3)烷基,羟基或(C1-3)烷氧基,条件是R4仅在Y = C时存在,R5仅在Z = C时存在,但当X和Z为N,Y为C,R4为Cl时, R5和R6为H,myn为零(0),且R2为H,R3不是碘或1,2,3,6-四氢吡啶-4-基;前提是当X为N,Y和Z为C时,R4为Cl,R5为Br,R6为H,m和n为零(0),且R3为H,R2不为碘或H。前提是当X和Z为C,Y为N,R5为羟基,R2,R4和R6为H,m和n为零(0)时,R3不是1,2,3,6-四氢吡啶-4 -当X为N时,Y和Z为C,myn为零(0),R2,R3,R4和R5为H,R6不为氯或氟,条件是X为N时,Y和Z为C,myn为零(0),R2,R3,R4和R6为H,R5不为溴,氯或氟,条件是当X为N,Y和Z为C时,m为1, n为零(0),R2,R4,R5和R6为H,R3不是乙基或吗啉-4-基,条件是当X为N,Y和Z为C时,m和n为零(0 ),R2,R4,R5和R6为H,R3不是溴,条件是当X为N,Y和Z为C时,m和n为零(0),R2,R3,R5和R6为H ,R 4不是氯,条件是当X是N,Y和Z是C时,m是零(0),n是1,R 3,R 4,R 5和R 6是H,R 2不是氢或吡啶-4 -yl,条件是当X为N,Y和Z为C时,m为零(0),n为1,R4,R5和R6 ar在H中,R 3是溴,R 2不是吡啶-4-基,2-甲基吡啶基-4-基,-乙基吡啶基-4-基或吗啉-4-基。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号